Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

January 25, 2024

https://www.globenewswire.com/news-release/2024/01/25/2816694/0/en/Kronos-Bio-Implements-New-Leadership-Structure-to-Drive-Pipeline-Advancement.html

SAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a streamlined leadership structure designed to focus on pipeline advancement and align with Kronos Bio’s current operating needs. As part of this effort, Kronos Bio has eliminated three executive officer roles including the Chief Medical Officer, Chief Scientific Officer, and Chief Operating Officer and General Counsel. As a result, Jorge DiMartino, M.D., Ph.D., Christopher Dinsmore, Ph.D., and Barbara Kosacz, J.D., will be departing the Company. To ensure a smooth transition, they will remain with the Company through February 16, 2024. All three executives will remain strategic advisors to Kronos Bio.

Read more at globenewswire.com

Related news for (KRON)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.